Brief: Repare Therapeutics Presents Initial Clinical Data From The Phase 1/2 Tresr And Attacc Trials

Repare Therapeutics

18/04/2023 20:54

April 18 (Reuters) - Repare Therapeutics Inc  RPTX.O :
    * REPARE THERAPEUTICS PRESENTS INITIAL CLINICAL DATA FROM
THE
PHASE 1/2 TRESR AND ATTACC TRIALS EVALUATING CAMONSERTIB IN
COMBINATION WITH THREE PARP INHIBITORS AT THE 2023 AACR ANNUAL
MEETING
    * REPARE THERAPEUTICS- COMBINATION RESULTS SHOWED MOST
BENEFIT IN
LATE-LINE OVARIAN CANCER DEMONSTRATING 32% OVERALL RESPONSE, 58%
CBR, MPFS OF ABOUT 7 MONTHS
    * REPARE THERAPEUTICS-EARLY CTDNA MOLECULAR RESPONSES IN 66%
OF
EVALUABLE PATIENTS CONFIRMS ANTITUMOR ACTIVITY OF LOW DOSE
INTERMITTENT PARPI + ATRI THERAPY

Source text for Eikon:  ID:nBw1BrL10a 
Further company coverage:  RPTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))